LYB — LyondellBasell Industries N.V.

The market is split, not fearful or greedy. The July 31, 2026 Q2 print was a genuine beat ($4.30 ex-items vs ~$3.44 consensus, EBITDA ex-items $2.1B), yet the stock has gone nowhere: +0.27% over one week, +1.42% over one month, -1.38% over three months and -11.91% over six months as of 2026-09-13, with RSI at 49.94. Sell-side is genuinely divided - FMP's rating breakdown shows 1 strong buy / 18 buy / 17 hold / 4 sell, and the $69.63 average target (11 analysts, range $62-$83) implies only ~9% upside, while JP Morgan went the other way with an Overweight and an $80 target in early August. The market is treating Q2 as a real inflection it doesn't yet trust, because the trailing numbers still carry 2025's damage (-$892M net income in Q3 2025, -$140M in Q4 2025).

This is a cyclical trough that has clearly turned, though only one quarter of evidence exists so far. Revenue collapsed from $10.63B in Q3 2023 to a flat ~$7.1-7.7B base across every quarter of 2025 and Q1 2026, then jumped to $9.18B in Q2 2026 (+19.8% YoY, +27.5% QoQ). Margins tell the same story: gross margin bottomed at 6.5% in Q4 2025, recovered to 9.7% in Q1 2026, then exploded to 22.2% in Q2 2026; operating margin went -0.6% (Q4 2025) to 3.3% (Q1 2026) to 16.8% (Q2 2026); diluted EPS went -$0.45 to $0.39 to $1.72 GAAP ($4.30 ex-items). The drivers were real but partly non-repeating: a $0.30/lb polyethylene contract price increase and lower local production costs in O&P Americas (segment EBITDA $1.3B), offset by a ~$250M hit from unplanned Bayport PO/TBA downtime in Intermediates & Derivatives. Cash remains lumpy, not consistently positive: TTM free cash flow is only ~$600M when you sum Q3 2025 ($577M), Q4 2025 ($79M), Q1 2026 (-$538M) and Q2 2026 ($482M). Verdict: inflection, not structural decline - but the durability test is Q3 2026, when operating rates normalize to ~85% on Clinton maintenance.

Fair-to-cheap on normalized earnings, not cheap on anything trailing. As of 2026-09-13 the TTM P/E of -56.9 (on EPS of -$1.077) is meaningless, and the 0.051 PEG is a statistical artifact of a negative earnings base. Forward math is where the debate lives: at $63.71, the next-FY consensus EPS of $9.328 implies a 6.8x forward P/E versus a 5-year average P/E of 11.26 - optically half-price. Two caveats keep me from calling it a bargain. First, P/S is 0.659 against a 5-year average of 0.60, i.e. a slight premium to its own history, not a discount. Second, that 6.8x multiple is the market's way of saying the $9.33 estimate is above mid-cycle. Leverage is real: long-term debt $11.22B against $10.67B of equity (D/E 1.33), and the 5.28% dividend (~$3.36/share, roughly $1.09B a year) is not covered by TTM FCF of ~$600M. On EV/EBITDA the same distortion appears in reverse - 17.0x trailing (depressed EBITDA of ~$1.7B) versus roughly 3.5x on Q2 2026's annualized run-rate. Neither number is the truth; mid-cycle is somewhere between.

At $63.71 on 2026-09-13, the stock is not pricing in the recovery it just reported - it's pricing in scepticism about it. On the $9.328 next-FY consensus estimate the multiple is 6.8x; even after I haircut normalized EPS to $8.25 the multiple is only 7.7x. Either the market disbelieves the estimate outright, or it believes 2026-2027 is a cyclical peak that fades. That distinction is the whole trade: if the $0.30/lb polyethylene price gain holds and Bayport volumes come back, forward EPS is roughly right and the stock is genuinely cheap; if those margins roll off, realistic EPS could be $4-5 and the P/E is really ~13-16x on a leveraged balance sheet with an uncovered dividend. Watch two things: (1) the Q3 2026 report in late October 2026, which is the first read on whether the pricing/feedstock spread survived the Clinton turnaround, and (2) whether Q3 EPS ex-items lands anywhere near the ~$4 run-rate implied by Q2, or drops back toward $1-2.

As of 2026-09-13, RSI(14) of 49.94 is textbook neutral - no oversold bounce to buy and no overbought exhaustion to sell. Price of $63.71 sits 1.62% below the 20-day SMA (~$64.76), 3.57% above the 50-day (~$61.51) and 4.57% above the 200-day (~$60.93): a mild uptrend that has flattened into a range over the past one to three months (+1.42% over a month, -1.38% over three months). The 52-week range of $41.58-$83.94 shows a stock that has rallied ~53% off the low but is still ~24% below the high - mid-recovery consolidation, not a breakout or a breakdown. Beta of 0.353 means index moves barely matter here; this is a feedstock-and-pricing story. Timing implication: there is no technical urgency either way, so scaling in nearer the 50-day (~$61.5) is a better entry discipline than chasing at $63.71, and the risk of waiting is that Q3 late-October results gap the stock before you get filled.

• Middle East geopolitical instability has steepened the global cost curve, which helps low-cost US ethane-based producers like LYB's O&P Americas segment but adds feedstock and logistics volatility quarter to quarter.
• Demand is diverging: data centre infrastructure, wire/cable, healthcare and pipe applications are healthy, while residential housing and automotive remain subdued - keeping a broad cyclical lid on polyolefin volumes.
• Circular-economy regulation in Europe and North America (recycled-content mandates) raises compliance capex and margin drag; LYB is managing it through circular JVs (Toyota Europe maritime waste polymers, Mondelez packaging) but the capital cost is real.
• Global industrial/PMI cycle remains the dominant variable - without a manufacturing recovery, polyolefin spreads stay compressed regardless of company-level execution.
• Europe's high-cost olefins position is structurally challenged, which is why LYB is divesting and assessing European assets - better long-run cost structure, but recurring restructuring charges and lower revenue.

• Q3 2026 earnings in late October 2026 (est. Oct 22-30) - the acid test for whether Q2's polyethylene price and feedstock spread survived operating-rate normalization to ~85% on Clinton maintenance.
• Bayport PO/TBA ramp-up and operational stability: reversing even part of the ~$250M Q2 hit inside Intermediates & Derivatives would be a clean, non-price-driven earnings add.
• Delivery of the incremental $500M Cash Improvement Plan by end-2026 (fixed cost reduction, lower capex) - directly relevant to whether the dividend stays covered.
• Completion of further European portfolio divestitures, improving the cost base and removing drag from the segment.
• Any sustained industry polyethylene price discipline or competitor capacity rationalization, which would support the forward $9.33 EPS estimate.

• Dividend coverage: roughly $1.09B of annual dividends against ~$600M of TTM free cash flow (Q1 2026 alone was -$538M). A cut to the 5.28% yield would likely be the single worst outcome for the share price and is not in the bull case.
• Balance sheet leverage: $11.22B long-term debt versus $10.67B equity (D/E 1.33) leaves limited cushion if the chemical cycle rolls back over before earnings normalize.
• Peak-margin risk: Q2 2026's profitability was flattered by a $0.30/lb polyethylene contract price increase and unusually low production costs - exactly the kind of spread that reverts. The 6.8x forward P/E may be correct scepticism rather than an anomaly.
• Operational reliability: unplanned downtime cost ~$250M in a single quarter (Bayport PO/TBA), and the asset base has a history of these events.
• Structural/regulatory: recycled-content mandates and long-run pressure on virgin plastics demand cap the terminal growth case and keep capital tied up in circularity projects with sub-par returns.

A reasonable, not compelling, cyclical recovery play - and I would not call it a buy at $63.71 as of 2026-09-13. The trough is very likely behind it: revenue +19.8% YoY, operating margin 16.8% and $559M of net income in Q2 2026 prove real operating leverage exists on this asset base. But FY2025's losses still sit in the trailing figures, TTM free cash flow (~$600M) does not cover the dividend (~$1.09B), leverage is high, and the 6.8x forward P/E only looks cheap if you trust a consensus estimate the sell-side's own $69.63 average target plainly discounts. Risk and reward are roughly balanced, with the honest path being to wait for the late-October Q3 report to confirm whether the polyethylene spread held before committing capital.

I used a normalized mid-cycle EPS multiplied by a justified P/E: I start from the next-FY consensus EPS of $9.328 and haircut it to $8.25 to strip out the non-recurring $0.30/lb polyethylene contract spike and the Bayport outage drag embedded in Q2 2026, then apply 9.5x - below the stock's 5-year average P/E of 11.26 - to reflect D/E of 1.33 and a dividend payout running ahead of trailing free cash flow. That yields ~$78, above the $69.63 sell-side average target (which implicitly applies only ~7.5x) and below the $83 high, consistent with a mid-cycle recovery that is real but not yet proven.